Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy

Journal of Urology

Volumn 157, Issue 4, 1997, Pages 1322-1328

  Witherspoon, Lynn R ^a   Lapeyrolerie, Toki ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

prostate specific antigen; prostatectomy; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

EID: 0030896823     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64962-0     Document Type: Article

References (46)

1. Bardot, S. F.: Early detection and treatment of prostate cancer. J. Louisiana State Med. Soc., 146: 313, 1994.
2. Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., deKernion, J. B., Ratliff, T. L., Kavoussi, L. R., Waters, W. B., MacFarlane, M. T. Dalkin, B. L. and Southwick, P. C.: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol., 151: 1283, 1994.
3. Catalona, W. J., Smith, D. S., Ratliff, T. L. and Basler, J. W.: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. J.A.M.A., 270: 948, 1993.
4. Brendler, C. B. and Walsh, P. C.: The role of radical prostatectomy in the treatment of prostate cancer. CA, 42: 212, 1992.
5. Partin, A. W. and Oesterling, J. E.: The clinical usefulness of prostate specific antigen: update 1994. J. Urol., 152: 1358, 1994.
6. Oesterling, J. E.: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145: 907, 1991.
7. Ploch, N. R. and Brawer, M. K.: How to use prostate-specific antigen. Urology, suppl. 2, 43: 27, 1994.
8. Lange, P. H., Ercole, C. J., Lightner, D. J., Fraley, E. E. and Vessella, R.: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol., 141: 873, 1989.
9. Catalona, W. J.: Management of cancer of the prostate. New Engl. J. Med., 331: 996, 1994.
10. Vessella, R. L.: Trends in immunoassays of prostate-specific antigen: serum complexes and ultrasensitivity. Clin. Chem., 39: 2035, 1993.
11. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med., 317: 909, 1987.
12. Catalona, W. J.: Expectant management and the natural history of localized prostate cancer. J. Urol., 152: 1751, 1994.
13. Schmid, H.-P., McNeal, J. E. and Stamey, T. A.: Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer, 71: 2031, 1993.
14. Lange, P. H.: Future studies in localized prostate cancer. What should we think? What can we do? J. Urol., 152: 1932, 1994.
15. Armbruster, D. A.: Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin. Chem., 39: 181, 1993.
16. Prestigiacomo, A. F. and Stamey, T. A.: A comparison of 4 ultrasensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy. J. Urol., 152: 1515, 1994.
17. Yu, H., Diamandis, E. P., Prestigiacomo, A. F. and Stamey, T. A.: Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clin. Chem., 41: 430, 1995.
18. Takayama, T. K., Vessella, R. L., Brawer, M. K., Noteboom, J. and Lange, P. H.: The enhanced detection of persistent disease after prostatectomy with a new prostate specific antigen immunoassay. J. Urol., 150: 374, 1993.
19. Mione, R., Barichello, M., Sartorello, P., Leon, A., Banoli, P. and Gion, M.: Third-generation PSA: ultrasensitive or ultraprecise assay? Int. J. Biol. Markers, 10: 229, 1995.
20. Stenman, U. H., Hakama, M., Knekt, P., Aromaa, A., Teppo, L. and Leinonen, J.: Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet, 344: 1594, 1994.
21. Witherspoon, L. R., Babson, A. L. and Olson, D. R.: IMMULITE chemiluminescent immunoassay system. In: Immunoassay Automation: An Updated Guide to Systems. Edited by D. W. Chan. San Diego, California: Academic Press, Inc., pp. 103-130, 1996.
22. Stamey, T. A.: Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994. Urology, 45: 173, 1995.
23. Oesterling, J. E., Chan, D. W., Epstein, J. I., Kimball, A. W., Jr., Bruzek, D. J., Rock, R. C., Brendler, C. B. and Walsh, P. C.: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol., 139: 766, 1988.
24. Parker, S. L., Tong, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 1996. CA, 46: 5, 1996.
25. Albertsen, P. C., Fryback, D. G., Storer, B. E., Kolon, T. F. and Fine, J.: Long-term survival among men with conservatively treated localized prostate cancer. J.A.M.A., 274: 626, 1995.
26. Woolf, S. H.: Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. New Engl. J. Med., 333: 1401, 1995.
27. Gann, P. H., Hennekens, C. H. and Stampfer, M. J.: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. J.A.M.A., 273: 289, 1995.
28. Garnick, M. B.: Prostate cancer: screening, diagnosis, and management. Ann. Intern. Med., 118: 804, 1993.
29. Lu-Yao, G., McLerran, D., Wasson, J. and Wennberg, J.: An assessment of radical prostatectomy. J.A.M.A., 269: 2633, 1993.
30. Graves, H. C. B., Wehner, N. and Stamey, T. A.: Ultrasensitive radioimmunoassay of prostate-specific antigen. Clin. Chem., 38: 735, 1992.
31. Liedtke, R. J., Kroon, G. and Batjer, J. D.: Modified assay of prostate-specific antigen with a detection limit <0.1 micro-gram/l. Clin. Chem., 39: 2150, 1993.
32. Yu, H. and Diamandis, E. P.: Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin. Chem., 39: 2108, 1993.
33. Vieira, J. G., Nishida, S. K., Pereira, A. B., Arraes, R. F. and Verreschi, I. T.: Serum levels of prostate-specific antigen in normal boys throughout puberty. J. Clin. Endocr. Metab., 78: 1185, 1994.
34. Leinonen, J., Lövgren, T., Vornanen, T. and Stenman, U. H.: Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. Clin. Chem., 39: 2098, 1993.
35. Klee, G. G., Preissner, C. M. and Oesterling, J. E.: Development of a highly sensitive immunochemiluminometric assay for prostate-specific antigen. Urology, 44: 76, 1994.
36. Dnistrian, A. M., Schwartz, M. K., Smith, C. A., Nisselbaum, J. S. and Fair, W. R.: Abbott IMx evaluated for assay of prostate-specific antigen in serum. Clin. Chem., 38: 2140, 1992.
37. Vessella, R. L., Noteboom, J. and Lange, P. H.: Evaluation of the automated Abbott IMx prostate-specific antigen (PSA) immunoassay. Clin. Chem., 38: 2044, 1992.
38. Yu, H. and Diamandis, E. P.: Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique. J. Urol., 153: 1004, 1995.
39. Ablin, R. J.: Prostate-specific antigen and the female prostate. Letter to the Editor. Clin. Chem., 35: 507, 1989.
40. Yang, N.: Endogenous antibody to prostate-specific antigen in women. Letter to the Editor. Clin. Chem., 34: 647, 1988.
41. Stamey, T. A., Graves, H. C. B., Wehner, N., Ferrari, M. and Freiha, F. S.: Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate-specific antigen. J. Urol., 149: 787, 1993.
42. Takayama, T. K., Vessella, R. L. and Lange, P. H.: A brief review of ultrasensitive prostate-specific antigen assays for the evaluation of patients after radical prostatectomy. World J. Urol., 11: 192, 1993.
43. Link, P., Freiha, F. S. and Stamey, T. A.: Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J. Urol., 145: 532, 1991.
44. Ruizeveld de Winter, J. A., Janssen, P. J., Sleddens, H. M., Verleun-Mooijman, M. C., Trapman, J., Brinkmann, A. O., Santerse, A. B., Schroder, F. H. and van der Kwast, T. H.: Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Amer. J. Path., 144: 735, 1994.
45. Goldrath, D. E. and Messing, E. M.: Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy. J. Urol., 142: 1082, 1989.
46. Leo, M. E., Bilhartz, D. L., Bergstralh, E. K. and Oesterling, J. E.: Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J. Urol., 145: 802, 1991.